FORGED IN INDUSTRY. BUILT FOR EMERGING BIOPHARMA.
The work between strategy and results is where we live.
A boutique partner for VC and PE-backed biopharma. Launch, market access, commercial transformation. Senior practitioners in the room with you, hands on the work from first call to last decision.
OUR CONVICTION.
We build from the inside out.
Not adjacent to it. Not advising someone in it. From global biopharmas and to start-ups. The decisions, the pressure, the consequences.
We've been in your seat.
No junior army. No standardized playbook. Configured precisely for this asset, this founder, this launch. Always designed for what the composition requires.
Built for Emerging BioPharma. Not for everything.
Advisory and execution are not separate engagements. We hold both threads from the same seat, at the same time. Strategy without execution is a document.
We think and execute, simultaneously.
Our scars are the product.
Friction-heavy launches, rebuilt strategies, difficult negotiations. That pattern recognition is what you're hiring. Not a framework or punch list. Judgment earned the hard way.
Instinct
Wins and hard-earned lessons both. We stopped counting when the knowing became instinct.
20+
Full-cycle launches. Pre-NDA through post-launch. The whole arc, every time.
25+
Acquisition, integration, and restructuring programs led from inside the commercial function. Not managed from a distance.
75+
Combined years specifically at the pre-commercial and founder-led stage. Where there's no playbook and everything gets built for the first time.
125+
Combined years across our core members, inside commercial functions where the decisions actually landed.
WHERE WE SHOW UP.
Every engagement starts with a situation.
We don't sell services. We meet you where the pressure is.
Threat &
New Entry
Competitive Entry
Defense without a plan is just a slower loss.
Coverage Loss / Crisis
When reinstatement came, nothing was left to chance.
Performance & Change
First Commercial Launch
Every assumption gets tested. Most don't survive contact.
Performance Plateau
The numbers are flat. The answer isn't. as easy as a report.
Launch & Growth
First Commercial Launch
Ecosystem operations gets tested. Launch readiness often fails at the system's seams.
Post-Launch Scaling
What got you to launch won't get you through growth.
Pre Market
Pre Launch Readiness
The infrastructure gap reveals itself at the worst possible time.
Indication Expansion
The evidence exists. The commercial architecture to carry the extra load doesn't.
WHAT WE DO.
Commercial capabilities built to remove obstacles.
We work between your team and the ecosystem around it: connecting evidence to access, access to execution.
Commercial Operations
The infrastructure that turns strategy into revenue.
Built to execute: stood up at the speed your stage demands.
-
Field force deployment and redesign
-
Field force effectiveness (FFE)
-
CSO strategy, design, and optimization
-
Turning performance data into revenue decisions
-
Converting formulary wins into scripts
Market Access
Without access, every other action fails to reach its potential.
Built for the market you're actually entering, not the one that looked good in the forecast.
-
Market Access & Trade Landscape Analyses and Strategy
-
Formulary access positioning and contracting
-
SP network optimization & contracting
-
MA & Trade integration with streamlined Patient Support Services
-
Prior auth pull-through strategy
-
Step therapy navigation and prescriber support
Clinical to Commercial
Clinical strategy is commercial strategy.
Built to close the gap between what the FDA approved and what the payer will cover.
-
Indication-specific value proposition and payer narrative
-
Evidence gap analysis for the new population
-
Label expansion and prescriber education strategy
-
Payer sequencing for new indication launch
-
Lifecycle positioning
OUR COMMERCIAL PHILOSOPHY.
The functions that determine outcome must be right first.
Commercial success is determined by what the label allows, what payers will cover, and what execution can convert. Every activity that follows builds on this foundation.
The Commercial Architecture
PERFORMANCE INTELLIGENCE
Measures and Refines
-
Analytics
-
Data Infrastructure
-
Competitive Intelligence
-
Finance
OPERATIONS INTEGRITY
Sustains and Protects
-
Legal
-
Compliance
-
Regulatory Affairs
-
HEOR post-approval
-
Access Vigilance
VOICE
Projects and Accelerates the Opportunity
-
Marketing
-
Brand
-
NPP
-
Digital
-
Medical Communications
-
Patient Engagement
THE COMMERCIAL ENGINE
Determines what is Commercially Achievable
-
Clinical to Commercial
-
Market Access
-
Commercial Operations
SCIENCE
Generates the Opportunity
-
R&D
-
Clinical Development
-
Medical Affairs
-
HEOR
-
Pharmacovigilance
Primary activities set the ceiling on everything else.
Primary activities determine the ceiling.
The label, the coverage, the conversion infrastructure: these set what every downstream function can achieve. No amount of marketing closes a coverage gap the label created.
Support activities can't compensate for primary failures.
A failed payer strategy can't be redeemed by better messaging. A label that doesn't support the indication can't be rescued by field excellence.
When primary activities are right, support activities thrive.
Coverage unlocked. Label positioned. Execution infrastructure stood up. Everything else amplifies from a foundation that holds.
HOW WE WORK.
Senior people. On the work. From day one.
No methodology decks. Experienced people oriented fast and focused on what matters.
We work as part of your team.
Same accountability, same standard, same skin in the game. The tools and partners already in the room stay in the room.
We start with your situation.
The diagnosis comes before the prescription, every time.
We move at the speed your stage demands.
Oriented in days. Decisive with incomplete information. The momentum carries.
We stay through the inflection points.
Until the work holds without us in the room.
THE TEAM.
Depth earned.
Not claimed.
Every engagement is led by a senior practitioner who has carried what you're carrying. The same people in the room at month six.
Paul Bragoli
Managing Partner
Market Access
He has spent his career inside the payer conversation. Across PBMs, national and regional plans, and the formulary committees that decide whether a therapy gets covered, gets restricted, or gets buried. He knows what moves payers, what stalls them, and where the leverage actually sits. That distinction is the whole job.
Craig Salmon-Gilmore
Commercial Effectiveness & Field Operations
He knows the difference between a formulary win and formulary pull-through. One is on paper. The other is what the field does every day after the access decision is made. That gap is where commercial performance either holds or quietly falls apart. Closing it is the work.
Andrew Joselyn
Trade, Distribution, & Channel Strategy
Thirty-one years of commercial pharma experience. Specialty pharmacy, trade, distribution, and the contracted relationships that determine whether a therapy actually reaches the patient. He has built the networks from scratch and run them at scale. The channel is where most launches quietly succeed or quietly fail.
Veron Browne, PhD
Clinical to Commercial
Translational & Clinical Strategy
Most organizations treat the transition from R&D to regulatory and commercial as a handoff. Veron treats it as the most consequential moment in the asset's life. Translational science, clinical strategy, and the evidence architecture that determines whether the molecule survives the gap between approval and access. PhD in Pharmacology and Toxicology. Founder of Alenvo, purpose-built regulatory intelligence for biotech and pharma.
Meghan Rivera
Executive Advisor
Commercialization Strategy
Early-stage companies don't fail on science alone. They fail when the path from approval to adoption isn't built. She shapes that path: commercial strategy, investor narrative, and the operating model required to turn an asset into a business.
W.H. Alvin Mok
Managing Partner
Transformation & Commercial Operations
The commercial infrastructure that determines whether a therapy reaches patients doesn't build itself. He builds it from the ground up for pre-commercial and emerging biopharma, where the first wrong decision determines the next eighteen months. The depth comes from having seen those same decisions play out at global scale.
ASH Annual Meeting
December 5 to December 8 | San Diego, CA
BioFuture Conference
October 27 to October 28 | New York, NY
BioPharma America
September 23 to September 24 | Boston, MA
Rare Trials Summit
September 14 to September16 | Boston, MA
Bio International Convention
June 22 to June 25 | San Diego, CA
CONNECT WITH US.
We're at the following events. Let's talk!
YOU'VE SEEN WHAT WE DO AND HOW WE THINK:
The difference is how we show up.
